Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Sponsor: Rarecells Diagnostics SAS
Summary
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
Official title: Clinical Study To Evaluate the Sensitivity of Circulating Iset® by Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Key Details
Gender
All
Age Range
35 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2024-11-13
Completion Date
2025-10-01
Last Updated
2025-06-11
Healthy Volunteers
No
Conditions
Interventions
CTC-DNA
ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
Locations (1)
Università Cattolica del Sacro Cuore Gemelli Hospital
Roma, Italy